Literature DB >> 24128414

Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF).

Juan Cordoba1, Meritxell Ventura-Cots2, Macarena Simón-Talero2, Àlex Amorós3, Marco Pavesi3, Hendrik Vilstrup4, Paolo Angeli5, Marco Domenicali6, Pere Ginés7, Mauro Bernardi6, Vicente Arroyo7.   

Abstract

BACKGROUND & AIMS: In spite of the high incidence of hepatic encephalopathy (HE) in cirrhosis, there are few observational studies.
METHODS: We performed an analysis to define the characteristics of HE and associated features using the database of the Canonic Study. Clinical, laboratory and survival data of 1348 consecutive cirrhotic patients admitted with an acute decompensation were compared according to the presence (n=406) or absence of HE and of acute-on-chronic liver failure (ACLF) (n=301).
RESULTS: HE development was independently associated with previous HE episodes; survival probabilities worsen in relation to the presence and grade of HE. There were marked differences between HE associated (n=174) and not associated (n=286) to ACLF. HE not associated with ACLF occurred in older cirrhotics, inactive drinkers, without severe liver failure or systemic inflammatory reaction and in relation to diuretic use. In contrast, HE associated with ACLF occurred in younger cirrhotics, more frequently alcoholics, with severe liver failure and systemic inflammatory reaction, and in relation to bacterial infections, active alcoholism and/or dilutional hyponatremia. Prognosis was relatively preserved in the first and extremely poor in the second group. Independent risk factors of mortality in patients with HE were age, bilirubin, INR, creatinine, sodium, and HE grade.
CONCLUSIONS: In cirrhosis, previous HE identifies a subgroup of patients that is especially vulnerable for developing new episodes of HE. The course of HE appears to be different according to the presence of ACLF.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (CLIF); ACLF; ALT; AST; Acute-on-chronic liver failure; Cirrhosis; EASL-Chronic Liver Failure; GGT; HE; Hepatic encephalopathy; INR; International Normalized Ratio; MELD; Risk factors; SOFA; Sequential Organ Failure Assessment; WBC; acute-on-chronic liver failure; alanine aminotransferase; aspartate aminotransferase; gamma-glutamyl transferase; hepatic encephalopathy; international normalized ratio; model for end-stage liver disease; n.s.; non significant; white blood cells

Mesh:

Year:  2013        PMID: 24128414     DOI: 10.1016/j.jhep.2013.10.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  86 in total

1.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

2.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.

Authors:  Shiv Kumar Sarin; Ashok Choudhury; Manoj K Sharma; Rakhi Maiwall; Mamun Al Mahtab; Salimur Rahman; Sanjiv Saigal; Neeraj Saraf; A S Soin; Harshad Devarbhavi; Dong Joon Kim; R K Dhiman; Ajay Duseja; Sunil Taneja; C E Eapen; Ashish Goel; Q Ning; Tao Chen; Ke Ma; Z Duan; Chen Yu; Sombat Treeprasertsuk; S S Hamid; Amna S Butt; Wasim Jafri; Akash Shukla; Vivek Saraswat; Soek Siam Tan; Ajit Sood; Vandana Midha; Omesh Goyal; Hasmik Ghazinyan; Anil Arora; Jinhua Hu; Manoj Sahu; P N Rao; Guan H Lee; Seng G Lim; Laurentius A Lesmana; Cosmas Rinaldi Lesmana; Samir Shah; V G Mohan Prasad; Diana A Payawal; Zaigham Abbas; A Kadir Dokmeci; Jose D Sollano; Gian Carpio; Ananta Shresta; G K Lau; Md Fazal Karim; Gamal Shiha; Rino Gani; Kemal Fariz Kalista; Man-Fung Yuen; Seema Alam; Rajeev Khanna; Vikrant Sood; Bikrant Bihari Lal; Viniyendra Pamecha; Ankur Jindal; V Rajan; Vinod Arora; Osamu Yokosuka; Madunil A Niriella; Hai Li; Xiaolong Qi; Atsushi Tanaka; Satoshi Mochida; Dominic Ray Chaudhuri; Ed Gane; Khin Maung Win; Wei Ting Chen; Mohd Rela; Dharmesh Kapoor; Amit Rastogi; Pratibha Kale; Archana Rastogi; Chhagan Bihari Sharma; Meenu Bajpai; Virender Singh; Madhumita Premkumar; Sudhir Maharashi; A Olithselvan; Cyriac Abby Philips; Anshu Srivastava; Surender K Yachha; Zeeshan Ahmad Wani; B R Thapa; Anoop Saraya; Ashish Kumar; Manav Wadhawan; Subash Gupta; Kaushal Madan; Puja Sakhuja; Vivek Vij; Barjesh C Sharma; Hitendra Garg; Vishal Garg; Chetan Kalal; Lovkesh Anand; Tanmay Vyas; Rajan P Mathur; Guresh Kumar; Priyanka Jain; Samba Siva Rao Pasupuleti; Yogesh K Chawla; Abhijit Chowdhury; Shahinul Alam; Do Seon Song; Jin Mo Yang; Eileen L Yoon
Journal:  Hepatol Int       Date:  2019-06-06       Impact factor: 6.047

3.  Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.

Authors:  Elliot B Tapper; Daniel Finkelstein; Murray A Mittleman; Gail Piatkowski; Michelle Lai
Journal:  Hepatology       Date:  2015-04-28       Impact factor: 17.425

Review 4.  Acute-on-Chronic Liver Failure.

Authors:  Sumeet K Asrani; Douglas A Simonetto; Patrick S Kamath
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-15       Impact factor: 11.382

5.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.

Authors:  Shiv Kumar Sarin; Chandan Kumar Kedarisetty; Zaigham Abbas; Deepak Amarapurkar; Chhagan Bihari; Albert C Chan; Yogesh Kumar Chawla; A Kadir Dokmeci; Hitendra Garg; Hasmik Ghazinyan; Saeed Hamid; Dong Joon Kim; Piyawat Komolmit; Suman Lata; Guan Huei Lee; Laurentius A Lesmana; Mamun Mahtab; Rakhi Maiwall; Richard Moreau; Qin Ning; Viniyendra Pamecha; Diana Alcantara Payawal; Archana Rastogi; Salimur Rahman; Mohamed Rela; Anoop Saraya; Didier Samuel; Vivek Saraswat; Samir Shah; Gamal Shiha; Brajesh Chander Sharma; Manoj Kumar Sharma; Kapil Sharma; Amna Subhan Butt; Soek Siam Tan; Chitranshu Vashishtha; Zeeshan Ahmed Wani; Man-Fung Yuen; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2014-09-26       Impact factor: 6.047

6.  Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis.

Authors:  Nicolas Weiss; Matteo Rosselli; Sarah Mouri; Damien Galanaud; Louis Puybasset; Banwari Agarwal; Dominique Thabut; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2016-10-11       Impact factor: 3.584

7.  Understanding paracetamol-induced liver failure.

Authors:  Fin Stolze Larsen; Julia Wendon
Journal:  Intensive Care Med       Date:  2014-04-16       Impact factor: 17.440

Review 8.  Altered Microbiome in Patients With Cirrhosis and Complications.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

Review 9.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.

Authors:  A Choudhury; A Jindal; R Maiwall; M K Sharma; B C Sharma; V Pamecha; M Mahtab; S Rahman; Y K Chawla; S Taneja; S S Tan; H Devarbhavi; Z Duan; Chen Yu; Q Ning; Ji Dong Jia; D Amarapurkar; C E Eapen; A Goel; S S Hamid; A S Butt; W Jafri; D J Kim; H Ghazinian; G H Lee; Ajit Sood; L A Lesmana; Z Abbas; G Shiha; D A Payawal; A K Dokmeci; J D Sollano; G Carpio; G K Lau; F Karim; P N Rao; R Moreau; P Jain; P Bhatia; G Kumar; S K Sarin
Journal:  Hepatol Int       Date:  2017-08-30       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.